TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19824837
Drug: Respeto/Proteger: Respecting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respeto/Proteger: Respecting and Protecting Our Relationships program; details on dosage and duration not available.
Study: 16395251
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin C (VC) infusion, n=20
Study: 30538796
Drug: Ropivacaine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (200 mg intraoperative, 100 mg postoperative every 8 hours for 2 days)
Study: 24710974
Drug: OT plus
Normalized name: Picot Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: OT plus EMG‐biofeedback therapy
Study: 24710974
Drug: OT plus
Normalized name: Picot Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: OT plus neurofeedback therapy
Study: 18096137
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion SR (300 mg/day) + Transdermal Nicotine Patch (21 mg/24h)
Study: 18096137
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Transdermal Nicotine Patch (21 mg/24h)
Study: 16155368
Drug: Etanercept (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (25 mg subcutaneously twice weekly for 4 weeks)
Study: 22120913
Drug: Chronic transfusion
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic transfusion therapy
Study: 10808175
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (40 mg/day) for 9 days
Study: 1325348
Drug: Phosphatidylserine 800
Normalized name: Phosphatidylserine
DrugBank: Phosphatidyl serine (DB00144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphatidylserine 800 mg/d for 10 days
Study: 558548
Drug: Pindolol 15
Normalized name: pindolol 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol 15 mg daily
Study: 6617682
Drug: Pindolol (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (for patients starting therapy later than 5 days after myocardial infarction)
Study: 6617682
Drug: Pindolol (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (for patients starting therapy after 12 days)
Study: 6617682
Drug: Pindolol (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (for patients on digitalis therapy)
Study: 22324753
Drug: Multifaceted Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifaceted Group (MG; n = 73)
Study: 18929280
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia with 7.5 mg of 0.5% hyperbaric bupivacaine
Study: 18929280
Drug: Combined sciatic-femoral
Normalized name: Sus scrofa temporal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined sciatic-femoral nerve blocks using a mixture of 20 mL of lidocaine 2% plus 20 mL of bupivacaine 0.5%
Study: 12390617
Drug: Buccal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal placebo
Study: 12390617
Drug: Oral ergotamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ergotamine tartarate (ERG) 1 mg plus caffeine 100 mg
Study: 30850957
Drug: CT-P16 5
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-P16 5 mg/kg
Study: 30850957
Drug: EU-bevacizumab 5
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: EU-bevacizumab 5 mg/kg
Study: 30850957
Drug: US-bevacizumab 5
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: US-bevacizumab 5 mg/kg
Study: 25600659
Drug: 1110 MBq
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1110 MBq I‐131 (low dose)
Study: 25600659
Drug: 3700 MBq
Normalized name: dotatate
DrugBank: Dotatate (DB14554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3700 MBq I‐131 (standard dose)
Study: 17319338
Drug: Intraoperative intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative intravenous diclofenac (1 mg/kg i.v. after induction followed by an infusion of 1 mg/kg over 2 hours)
Study: 10886272
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no oral isotretinoin)
Study: 18273733
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (Lantus) daily from start of surgery
Study: 18273733
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin (Actrapid) when needed (sliding scale)
Study: 12170023
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of methylprednisolone (10 mg/kg body weight) 30 minutes before surgery (MP group)
Study: 23812272
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion (control group)
Study: 12170023
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of methylprednisolone (MP group)
Study: 10565450
Drug: Insulin-dependent diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-dependent diabetes mellitus (IDDM) patients
Study: 31956723
Drug: Cognitive-behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavior therapy (CBT)
Study: 30498987
Drug: Cognitive-behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavior therapy (CBT) or Dialectical-behavior therapy (DBT)
Study: 25377933
Drug: MK-3207 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-3207 (20 mg dose)
Study: 25377933
Drug: MK-3207 (40-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-3207 (40-100 mg dose)
Study: 25377933
Drug: CGRP receptor
Normalized name: CGRP
DrugBank: Calcitonin gene-related peptide (DB06379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGRP receptor antagonists
Study: 23728118
Drug: Prescription chart
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription chart design from NHS Highland
Study: 23728118
Drug: Prescription chart
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription chart design from NHS Grampian
Study: 23728118
Drug: Other three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other three prescription chart designs
Study: 23728118
Drug: Time taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time taken to complete prescriptions
Study: 16171630
Drug: IA tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA tramadol 50 mg
Study: 10421669
Drug: Consensus interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consensus interferon (CIFN) 15 mcg for 12 months
Study: 10421669
Drug: Initial interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial interferon treatment (either 9 mcg CIFN or 3 MU IFN-alpha2b 3 times per week)
Study: 30678465
Drug: n3PUFA (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: n3PUFA (4 g/d)
Study: 2026848
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous immunoglobulin (IVIG)
Study: 9725477
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ipriflavone tablets three times daily
Study: 9725477
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg Scherer capsules twice daily
Study: 7975835
Drug: Booster vaccine
Normalized name: Moderna COVID-19 (6y+) Bivalent Booster Vaccine PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster vaccine (5 infants)
Study: 7975835
Drug: One-dose vaccine
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-dose vaccine (18 infants)
Study: 2658898
Drug: Subcutaneous porcine
Normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous porcine intestinal mucosal heparin
Study: 2658898
Drug: Porcine intestinal
Normalized name: porcine intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porcine intestinal mucosal heparin (both routes)
Study: 4976123
Drug: Trasicor (beta-adrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trasicor (beta-adrenergic blocking drug)
Study: 31285738
Drug: Single strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single strain probiotics, once daily for fourteen days
Study: 24601169
Drug: 7-day therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day therapy with omeprazole (20 mg b.i.d.), levofloxacin (500 mg o.i.d.), and amoxicilline (1000 mg b.i.d.)
Study: 24601169
Drug: 10-day therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-day therapy with omeprazole (20 mg b.i.d.), levofloxacin (500 mg o.i.d.), and amoxicilline (1000 mg b.i.d.)
Study: 24601169
Drug: Both 7-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both 7-day and 10-day therapies
Study: 15261932
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg irbesartan (IRB)
Study: 15261932
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg enalapril (ENAL)
Study: 11600825
Drug: Nelfinavir 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelfinavir 750 mg tid + ZDV 200 mg tid + 3TC 150 mg bid
Study: 11600825
Drug: Nelfinavir 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelfinavir 500 mg tid + ZDV 200 mg tid + 3TC 150 mg bid
Study: 11600825
Drug: ZDV 200
Normalized name: ZDV
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ZDV 200 mg tid + 3TC 150 mg bid + placebo
Study: 9636854
Drug: Sparfloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparfloxacin (200 mg once daily following a 400 mg loading dose on day 1)
Study: 9636854
Drug: Amoxicillin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (1 g oral dose three times daily)
Study: 8601365
Drug: ursodiol, 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ursodiol, 1200 mg/day
Study: 19137905
Drug: Estomine‐zee (escitalopram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estomine‐zee (escitalopram oxalate 10 mg and clonazepam 0.5 mg)
Study: 19137905
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available formulation (escitalopram oxalate 10 mg and clonazepam 0.5 mg)
Study: 30987852
Drug: RSV F
Normalized name: Respiratory syncytial virus fusion protein.
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSV F subunit vaccine with aluminum hydroxide adjuvant
Study: 30987852
Drug: RSV F
Normalized name: Respiratory syncytial virus fusion protein.
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSV F subunit vaccine with MF59 adjuvant
Study: 14685005
Drug: Pimagedine 150
Normalized name: pimagedine
DrugBank: Pimagedine (DB05383)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimagedine 150 mg
Study: 14685005
Drug: Pimagedine 300
Normalized name: pimagedine
DrugBank: Pimagedine (DB05383)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimagedine 300 mg
Study: 14685005
Drug: Pimagedine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimagedine (both doses)
Study: 15163329
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg MMI
Study: 28557652
Drug: Clomiphene Citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene Citrate (CC)
Study: 29426811
Drug: Excision with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excision with corticosteroid injections
Study: 24750284
Drug: Pasireotide 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 300 μg s.c. t.i.d.
Study: 16417414
Drug: Sex hormone-binding
Normalized name: Testosterone bound to sex hormone-binding globulin (SHBG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sex hormone-binding globulin (SHBG)
Study: 11302008
Drug: Berry group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berry group (100 g of deep-frozen berries daily for 8 weeks)
Study: 11302008
Drug: Supplement group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement group (100 mg of alpha-tocopherol and 500 mg of ascorbic acid daily)
Study: 1425135
Drug: Oral Acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Acyclovir
Study: 30478992
Drug: Fasting glucose
Normalized name: FAST TAKE (GLUCOSE) METER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting glucose levels categorized as <6.1 mmol/l (reference), 6.1-7.0 mmol/l (2nd), ≥7.0 mmol/l (3rd)
Study: 30439313
Drug: Ordinary flow
Normalized name: ordinary salt combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary flow device and warm and humid exchanger (artificial nose, HME) passive humid oxygen therapy
Study: 26252574
Drug: D-mix (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-mix (3 g/dose)
Study: 12684289
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy alone (Control)
Study: 15800664
Drug: Candesartan-based antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan-based antihypertensive treatment
Study: 11916549
Drug: Conventional fractionation
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fractionation (CF) with 70 Gy in 7 weeks, 2 Gy per fraction, daily dose of 6 mg/m² cisplatin
Study: 11916549
Drug: Modified fractionation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified fractionation (MFD) with three fractions of 1.6 Gy per day, daily dose of 10 mg/m² cisplatin
Study: 345489
Drug: LH-RH in
Normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LH-RH in combination with human menopausal gonadotrophins (HMG)
Study: 25670361
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g of almonds daily for 4 weeks
Study: 23302220
Drug: Mesalazine (2g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine (2g granules taken up to twice a day for 12 weeks)
Study: 23302220
Drug: Placebo granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo granule formulation
Study: 21530092
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy/Motivational Enhancement Therapy (CBT/MET)
Study: 21530092
Drug: Naturalistic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naturalistic treatment (Control)
Study: 19233049
Drug: Methotrexate and
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate and other disease-modifying anti-rheumatic drugs (DMARDs)
Study: 12638400
Drug: Ketoprofen 75
Normalized name: ketoprofen 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 75 mg qid for 3 days
Study: 12953342
Drug: Acetaminophen 1000
Normalized name: acetaminophen 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1000 mg qid for 3 days
Study: 19682321
Drug: Ziconotide (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziconotide (in combination with other IT agents)
Study: 8302193
Drug: Flunitrazepam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (1 mg)
Study: 1982881
Drug: Quazepam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quazepam (15 mg)
Study: 11641942
Drug: Epifamine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epifamine (400 mg course dose)
Study: 15328675
Drug: Azelastine nasal
Normalized name: azelastine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine nasal spray, 2 sprays per nostril twice daily plus fexofenadine, 60 mg twice daily
Study: 15328675
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) nasal spray and placebo capsules twice daily
Study: 9301445
Drug: Cisplatin (CDDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CDDP) 100 mg/m2 combined with 5-fluorouracil (5-FU) 1000 mg/m2 continuous infusion from days 1-5 (Arm A)
Study: 29505101
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg JNJ-54861911 once daily for 7 days
Study: 29505101
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg JNJ-54861911 once daily for 7 days
Study: 29505101
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg JNJ-54861911
Study: 27807925
Drug: Topiramate 75
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate 75 mg/day
Study: 25010303
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg plus sildenafil 50 mg
Study: 25010303
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg plus placebo
Study: 18367288
Drug: Thoracic radiotherapy
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic radiotherapy (TRT) with a planned dose of 50Gy in 2Gy daily fractions, initiated with the fourth chemotherapy cycle.
Study: 22036029
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg body weight
Study: 22036029
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg body weight
Study: 22036029
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg body weight
Study: 16088265
Drug: Mind-body therapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mind-body therapy (structured 60-hour training program over 10 weeks including stress management training, moderate exercise, Mediterranean diet, behavioral techniques and self-care strategies)
Study: 30260396
Drug: Oral glucose
Normalized name: glucose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucose tolerance test
Study: 134722
Drug: Atropine sulphate
Normalized name: Atropine sulphate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulphate by inhalation (1.6 mg and 2.4 mg)
Study: 134722
Drug: Atropine sulphate
Normalized name: Atropine sulphate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulphate by inhalation
Study: 134722
Drug: Ipratropiumbromide by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipratropiumbromide by inhalation
Study: 11454180
Drug: IFN 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN 4.5 MU daily plus amantadine 200 mg/day for 4 weeks and then IFN 6 MU thrice weekly plus amantadine 200 mg/day for an additional 5 months (group A)
Study: 11454180
Drug: IFN alone
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN alone at the same dosage and duration (group B)
Study: 26964861
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (Trendelenburg position)
Study: 24617731
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion with bone marrow‐derived mononuclear cells (BMMCs)
Study: 24617731
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion with peripheral blood‐derived mononuclear cells (PBMCs)
Study: 22137804
Drug: Liberal blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal blood glucose strategy (121‐180 mg/dL)
Study: 22137804
Drug: Strict blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strict blood glucose strategy (90‐120 mg/dL)
Study: 12628944
Drug: Roxithromycin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin (300 mg daily for 6 weeks)
Study: 24802769
Drug: Adaptive compression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive compression therapy (ACT) system
Study: 25191981
Drug: ATP infusion
Normalized name: ATP
DrugBank: ATP (DB00171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATP infusion (100 μg/kg/min)
Study: 17217450
Drug: NK-1 receptor
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: NK-1 receptor antagonist (NK-1RA)
Study: 9884136
Drug: Placebo beverages
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo beverages (1 ml alcohol)
Study: 9884136
Drug: 0.35 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.35 g/kg of alcohol beverages
Study: 7481209
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant systemic therapy (control)
Study: 2650582
Drug: Quinapril (20-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (20-80 mg/day)
Study: 2650582
Drug: Captopril (50-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50-200 mg/day)
Study: 21991732
Drug: Meperidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine (1 mg/kg)
Study: 352484
Drug: Thiopentone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (2.5 mg/sec)
Study: 28503725
Drug: Extraction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extraction treatment with fixed appliances for a mean period of 2.49 years
Study: 21321613
Drug: Oral rinse
Normalized name: Oral Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rinse of Turkish gall
Study: 21321613
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral hygiene only (Control)
Study: 17485971
Drug: Amlodipine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine + Valsartan combination therapy
Study: 17485971
Drug: Amlodipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (2.5 or 5 mg/d; 10 mg/d)
Study: 17485971
Drug: Valsartan (40,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (40, 80, 160, or 320 mg/d)
Study: 11437015
Drug: Fluoxetine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (10 mg daily for 2 weeks, then increased to 20 mg daily, with possible increase to 60 mg daily)